Peter H. Sayre

University of California, San Francisco — United States

Medicine · Health Sciences

35h-index8.1kcitations103works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(26), Food Allergy and Anaphylaxis Research(11), Monoclonal and Polyclonal Antibodies Research(11), Hematopoietic Stem Cell Transplantation(10), Immune Cell Function and Interaction(10)

Publications103 total

Impact of low disease burden on the safety and efficacy of BCMA CAR-T in patients with Relapsed/Refractory multiple myeloma
Blood·2025
Front-line treatment of Philadelphia negative B-cell acute lymphoblastic leukemia with hypercvad with blinatumomab
Blood·2025Open Access
Sequential BCMA- and GPRC5D-targeted bispecific antibody therapy in multiple myeloma: Real-world outcomes and first report of dual bispecific antibody-refractory patients
Blood·2025Open Access
Large language models extract diverse manifestations of chronic GVHD from unstructured clinical documentation
Blood·2025
Impact of prior BCMA-targeted therapy on CAR-T expansion and host T-cell phenotypes in patients with Relapsed/Refractory multiple myeloma receiving BCMA CAR-T therapy
Blood·2025
Outcomes of elderly patients with newly diagnosed multiple myeloma (NDMM): A retrospective comparison of daratumumab-based induction versus autologous stem cell transplant (autoSCT)
Blood·2025
How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy?
Immunotherapy·2025Open Access
Outcomes and Maintenance Strategies for Transplant-Eligible Newly Diagnosed Multiple Myeloma Among Patients Age 40 and Younger
Clinical Lymphoma Myeloma & Leukemia·2025
Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma
Leukemia & lymphoma/Leukemia and lymphoma·2025
Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review
Expert Opinion on Investigational Drugs·2025· 3 cited
A genome catalog of the early-life human skin microbiome
Genome biology·2023· 15 citedOpen Access
PB2498: A PHASE 1 STUDY OF WU-NK-101 IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
HemaSphere·2023Open Access
Supplementary Data from Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis
2023Open Access
Data from Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis
2023Open Access
Supplementary Data from Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis
2023Open Access
Supplementary Data from Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis
2023Open Access
Data from Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis
2023Open Access
Supplementary Data from Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis
2023Open Access
Supplementary Data from Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis
2023Open Access
Supplementary Data from Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Ellis L. Reinherz(9), George Du Toit(8), Henry T. Bahnson(8), Marshall Plaut(8), Gideon Lack(8), Graham Roberts(7), Suzana Radulović(7), Monica Basting(6), Jeffrey A. Bluestone(6), Stephen E. Gitelman(6), Lloyd E. Damon(6), Deborah Phippard(5), Michelle L. Sever(5), Peter A. Gottlieb(5), Matthew J. Wieduwilt(5), Linda K. Clayton(5), Linna Ding(5), Noha Lim(5), Judith Evind(5), Rebecca L. Olin(5)